Carl Schmid, MBA

August 06, 2021

Experts in HIV provide closing thoughts on the future of PrEP, including improvement of uptake and addressing access disparities.

August 05, 2021

Key opinion leaders in HIV describe factors to consider when evaluating which patients may benefit from long-acting injectable PrEP therapies.

August 04, 2021

A multidisciplinary panel of experts discuss pipeline medications for PrEP and effects of the USPSTF grading on emerging therapies.

July 28, 2021

Experts in HIV provide insight into the Grade A recommendation for HIV PrEP by the U.S. Preventive Services Task Force (USPSTF) and its impact on patients, clinicians, and payers.

July 28, 2021

Key opinion leaders in HIV discuss nonadherence to HIV PrEP and methods to address patient “walk away.”

July 21, 2021

Ian Frank, MD and Jeffrey Crowley, MPH provide insight into engaging clinicians for increased assessment of patients for PrEP.

July 21, 2021

Experts in HIV discuss methods to address the low rate of HIV PrEP uptake among at-risk individuals.

July 14, 2021

A multidisciplinary panel of experts discuss challenges to monitoring patient adherence and persistence to HIV PrEP.

July 14, 2021

Ian Frank, MD and Jeffrey Crowley, MPH address HIV PrEP adherence and persistence issues in the clinical practice setting.

July 07, 2021

Experts in HIV provide insight into payer coverage of HIV PrEP and patient barriers for receiving PrEP.